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1. Introduction 
Obstructive sleep apnea syndrome (OSAS) is a common disorder characterized by recurrent 
upper airway collapse during sleep. A reduction or complete cessation of airflow occurs 
despite ongoing inspiratory efforts and leads to arousals, sleep fragmentation, and 
oxyhemoglobin desaturation (Remmers et al., 1978; Young et al., 1993). 
Though clinically recognized for more than four decades (Gastaut et al., 1965), general 
awareness of OSAS has been slow to develop. OSAS has been associated with 
cardiovascular disease (Marin et al., 2005; Duran-Cantolla et al., 2010; Barbe et al., 2010), 
automobile accidents (Teran-Santos et al., 1999), chronic obstructive pulmonary disease 
(Chaouat et al., 1995), heart failure (Oldenburg et al., 2007) and health related quality of life 
deterioration (Pichel et al., 2004). OSAS often coexists with obesity and has been related to 
insulin resistance and metabolic syndrome (Choi et al., 2008).   
Patients with OSAS experience repetitive episodes of hypoxia and reoxygenation during 
transient cessation of breathing that may have systemic effects. These patients also present 
increased levels of biomarkers linked to endocrine-metabolic and cardiovascular alterations 
(Zamarron et al., 2008). Moreover, OSAS may involve sleep fragmentation, tonic elevation of 
sympathetic neural activity, oxidative stress, inflammation, hypercoagulability and 
endothelial dysfunction (Bradley & Floras, 2009; Fava et al., 2011). All of this indicates that 
OSAS should be considered a systemic disease rather than a local abnormality. 
The present review analyses the pathophysiology related to the systemic consequences of 
OSAS and the mechanisms involved in the association between OSAS and systemic diseases 
(Figure 1). 
2. Sleep fragmentation 
Extreme sleep habits can affect health and have been associated with increased 
inflammation. Significant changes in habitual sleep duration can lead to chronic low-grade 
systemic inflammation (Meisinger et al., 2005; Patel et al., 2009). Activation of pro-
inflammatory pathways may represent a mechanism. In a recent study in pediatric OSAS 
patients, increased TNF-ǂ levels were primarily driven by sleep fragmentation and body 
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mass index. These levels were closely associated with the degree of sleepiness, as measured 
by the Multiple Sleep Latency Test. Surgical treatment of OSAS resulted in significant 
reductions in TNF-ǂ levels with reciprocal prolongations in sleep latency (Gozal et al., 2010). 
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Fig. 1. A schematic summary of the proponed sequence of events in OSAS starting from 
episodic hypoxia and ending with systemic consequences. 
Sleep fragmentation increases sympathetic nervous activity, which, in turn, results in a 
higher metabolic rate and elevated catecholamine secretion. Furthermore, severe sleep 
fragmentation can disturb nocturnal renin and aldosterone secretion profiles, and increase 
nighttime urine excretion. Moller et al. found that long-term CPAP reduced blood pressure, 
which was correlated with reductions in plasma renin and angiotensin II levels (Moller et 
al., 2003). 
Although the mechanism of this altered inflammatory status in humans undergoing 
experimental sleep loss is unknown, it is likely that autonomic activation and metabolic 
changes play key roles (Mullington et al., 2010). 
3. Enhanced sympathetic traffic 
In OSAS patients, tonic activation of chemoreflex activity produces enhanced sympathetic 
traffic (Somers et al., 1988). Cyclic intermittent hypoxia (IH) and hypercapnia provides the 
causal link between upper airway obstruction during sleep and sympathetic activation 
during awakening. In a recent study in healthy humans, IH significantly increased 
sympathetic activity and daytime blood pressure after a single night of exposure. The 
baroreflex control of sympathetic outflow declined (Tamisier et al., 2011). Surges in 
sympathetic nervous system activity associated with apneic events have also been related to 
antifibrinolytic activity reflected by elevations in PAI-1 (von & Dimsdale, 2003). During 
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apneic events, there is an up-regulation of the renin-angiotensin system and down-
regulation of nitric oxide synthases (Fletcher et al., 1999; Prabhakar et al., 2001).  
The increased sympathetic activity and IH associated with apneic episodes has been 
proposed as a possible mechanism behind the association between OSAS, systemic 
inflammation and cardiovascular disease. CPAP reduces sympathetic nerve activity (Maser 
et al., 2008), increases arterial baroreflex sensitivity (Marrone et al., 2011) and decreases 
vascular risk (Kohler et al., 2008).  
4. Oxidative stress 
There is an emerging consensus that OSAS is an oxidative stress disorder. In a recent study 
involving children with OSAS, Malakasioti found an increase of hydrogen peroxide levels in 
exhaled breath condensate, which is an indirect index of altered redox status in the 
respiratory tract (Malakasioti et al., 2011). 
Apnea produces a decline in oxygen levels followed by reoxygenation when breathing 
resumes. The cyclical episodes of hypoxia-reoxygenation, analogous to cardiac 
ischemia/reoxygenation injury causing ATP depletion and xanthine oxidase activation, and 
increases the generation of oxygen-derived free radicals. CPAP therapy decreases the levels 
of oxidative stress in OSAS patients (Chin et al., 2000; Alonso-Fernandez et al., 2009). 
Oxidative stress can profoundly regulate the cellular transcriptome through activation of 
transcription factors, including specificity protein-1, hypoxia-inducible factor-1, c-jun, and 
possibly nuclear factor-kappaB. Activation of redox-sensitive gene expression is suggested 
by the increase in some protein products of these genes, including VEGF (Teramoto et al., 
2003), EPO (Marrone et al., 2008), endothelin-1 (Belaidi et al., 2009), inflammatory cytokines 
and adhesion molecules (Ohga et al., 1999; Dyugovskaya et al., 2002; Ohga et al., 2003).  
Increased oxidative stress has been associated with development of cardiovascular diseases 
and can be promoted by the chronic intermittent hypoxia characteristic of OSAS (Park et al., 
2007). A variety of studies suggest that oxidative stress is present in OSAS at levels relevant 
to tissues such as the arterial wall (Grebe et al., 2006; Barcelo et al., 2006). This process 
enhances lipid uptake into human macrophages and may contribute to atherosclerosis in 
OSAS patients (Lattimore et al., 2005). Furthermore, OSAS decreases blood antioxidant 
status in high BMI subjects and may change the relationship between oxidative stress 
markers (Wysocka et al., 2008). After CPAP, expression of eNOS and phosphorylated eNOS 
was found to be significantly increased whereas expression of nitrotyrosine and nuclear 
factor-kappaB significantly decreased (Jelic et al., 2010) but some studies shown that CPAP 
may not affect antioxidant defense (Alzoghaibi & Bahammam, 2011). 
Recently, Nair reported that oxidative stress is mediated, at least in part, by excessive 
NADPH oxidase activity. This author suggests that pharmacological agents targeting 
NADPH oxidase may provide a therapeutic strategy in OSAS (Nair et al., 2011). 
5. Systemic inflammation 
Local and systemic inflammation is present in OSAS. Insofar as local inflammation, bronchial 
and nasal changes are especially relevant (Devouassoux et al., 2007). In a recent study, patients 
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showed a significant increase in IL-8 and ICAM concentrations in both plasma and exhaled 
condensate. In addition, they showed a higher neutrophil percentage in induced sputum. 
These findings were significantly and positively correlated to AHI (Carpagnano et al., 2010), 
however, CPAP-therapy did have a significant effect (Lacedonia et al., 2011). 
Several studies have reported changes in circulating levels of adhesion molecules in OSAS 
patients (El-Solh et al., 2002; Zamarron-Sanz et al., 2006). Dyugovskaya analysed 
polymorphonuclear apoptosis and expression of adhesion molecules in vitro in patients 
with moderate to severe OSAS. Decreased apoptosis and increased expression of adhesion 
molecules were observed. Although adhesion molecules may facilitate increased 
polymorphonuclear-endothelium interactions, decreased apoptosis may further augment 
these interactions and facilitate free radical and proteolytic enzymes (Dyugovskaya et al., 
2008). 
OSAS patients present increased levels of inflammatory mediators such as TNF and IL-6 
(Imagawa et al., 2004; Bravo et al., 2007) that decrease with CPAP treatment (Arias et al., 
2008; Steiropoulos et al., 2009).  
Systemic inflammation is increasingly being recognized as a risk factor for a number of 
complications including atherosclerosis (Ross, 1999) and is a well-established factor in the 
pathogenesis of cardiovascular disease (Hansson, 2005). Certain acute-phase proteins that 
have been associated in humans with cardiovascular disease, such as serum amyloid 
(Svatikova et al., 2003), C-reactive protein (Taheri et al., 2007; Punjabi & Beamer, 2007) 
which have been associated in humans with cardiovascular disease are elevated in OSAS  
patients and improve with CPAP treatment (Yokoe et al., 2003; Kuramoto et al., 2009).  
The mechanisms by which inflammation contributes to OSAS-induced vascular dysfunction 
are not known. Reoxygenation after a brief period of hypoxia as experienced repetitively 
and systematically by OSAS patients may predispose to cell stress. It has been suggested 
that such events favor the activation of a proinflammatory response as mediated through 
the nuclear transcription factor nuclear factor-kappaB, a master regulator of inflammatory 
gene expression. 
Inflammation may be an important link between increased sympathetic nervous system 
activity and vascular dysfunction in OSAS. Chronically elevated sympathetic activity 
produced an inflammatory response in several organs and vascular beds (Yu et al., 2005). 
Some authors point to the role of the T-lymphocyte. This cell is known to play an important 
role in ANG II-induced hypertension and endothelial dysfunction via NADPH oxidase-
induced superoxide production (Guzik et al., 2007). 
Increased expression of inflammatory cytokines may contribute to endothelial dysfunction 
and subsequent cardiovascular complications (Ryan et al., 2005; Foster et al., 2007). 
Currently, some studies suggest that pentraxin 3, an acute phase response protein, is rapidly 
produced and released by several cell types, in particular by mononuclear phagocytes, and 
endothelial cells in response to primary inflammatory signals, may play a significant role in 
OSAS-associated vascular damage (Kasai et al., 2011). Arnaud report that some inhibition of 
molecules such as RANTES/CCL5, a cytokine that is a a selective attractant for memory T 
lymphocytes and monocytes may play a significant role in athesroscletoric remodeling  
OSAS-associated vascular damage  (Arnaud et al., 2011)  
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However, mesenchymal stem cells triggered an early anti-inflammatory response in rats 
subjected to recurrent obstructive apneas, suggesting that these stem cells could play a role 
in the physiological response to counterbalance inflammation in OSAS (Carreras et al., 
2010). 
In a recent study on healthy human males, Querido et al. analysed the effect over 10 days of 
nightly IH in the following systemic inflammatory markers: serum granulocyte macrophage 
colony-stimulating factor, interferon-gamma, interleukin-1 ǃ, interleukin-6, interleukin-8, 
leptin, monocyte chemotactic protein-1, vascular endothelial growth factor, intracellular 
adhesion molecule-1, and vascular cell adhesion molecule-1. There was no significant change 
in any of the markers. These findings suggest that a more substantial or a different pattern of 
hypoxemia might be necessary to activate systemic inflammation, that the system may need to 
be primed before hypoxic exposure, or that increases in inflammatory markers OSAS patients 
may be more related to other factors such as obesity or nocturnal arousal (Querido et al., 2011). 
6. Hypercoagulability 
Hypercoagulability resulting from increased coagulation or inhibited fibrinolysis is associated 
with an increased risk for cardiovascular disease (Zouaoui et al., 2006). This is another factor 
implicated in the association between this disease and OSAS (Peled et al., 2008). 
A variety of findings support the existence of a relation between hypercoagulability, OSAS 
and cardiovascular disease. Firstly, patients with OSAS present higher plasma levels of 
several procoagulant factors such as fibrinogen (Reinhart et al., 2002; Tkacova et al., 2008), 
activated clotting factor FVII, FXIIa and thrombin/antithrombin III complexes (von et al., 
2005) and the fibrinolysis-inhibiting enzyme plasminogen activator inihibitor (PAI-1) (von et 
al., 2006; Zamarron et al., 2008). Secondly, increased D-dimer levels in untreated OSAS have 
been correlated with severity of nocturnal hypoxemia, characteristic of OSAS (Shitrit et al., 
2005). Thirdly, sleep fragmentation and sleep efficiency data have been associated with 
increased levels of von Willebrand factor and soluble tissue factor, two markers of a 
prothrombotic state (von et al., 2007).  
OSAS is associated with platelet activation (Akinnusi et al., 2009). Platelet activation is a link 
in the pathophysiology of diseases prone to thrombosis and inflammation (Gasparyan et al., 
2011). In these patients, platelet activation is associated with greater levels of oxygen 
desaturation (Oga et al., 2009;Rahangdale et al., 2011) that decreases after CPAP treatment 
(Varol et al., 2011). 
In a current article, thromboelastography, a simple test of hemostasis, has been proposed for 
evaluating the risk of future cardiovascular disease in patients with OSAS (Othman et al., 
2010). 
7. Endothelial dysfunction 
Endothelial dysfunction is an early marker of vascular abnormality preceding clinically 
overt cardiovascular disease (Giannotti & Landmesser, 2007; Halcox et al., 2009). 
The intact endothelium regulates vascular tone and repair capacity, maintaining 
proinflammatory, anti-inflammatory, and coagulation homeostasis. Alteration of these 
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homeostatic pathways results in endothelial dysfunction before structural changes in the 
vasculature. The hypoxia, hypercapnia, and pressor surges accompanying obstructive 
apneic events may serve as potent stimuli for the release of vasoactive substances and for 
impairment of endothelial function.  
In OSAS, endothelial dysfunction could be caused by both hypoxia-reoxygenation cycles 
and chronic sleep fragmentation produced by repetitive arousals. A causal relationship 
between OSAS and endothelial dysfunction was demonstrated by a study in which flow-
mediated dilation in the forearm was improved by CPAP treatment (Ip et al., 2004; 
Trzepizur et al., 2009). Levels of nitric oxide, a major vasodilator substance released by the 
endothelium, have been found to be decreased in OSAS patients, and these levels normalize 
with CPAP therapy (Haight & Djupesland, 2003).  
A number of studies with OSAS patients indicate an associated endothelial dysfunction 
(Nieto et al., 2004). In patients with OSAS, increased production of superoxide by 
neutrophils (Schulz et al., 2000), increased biomarkers of lipid peroxidation (Lavie et al., 
2004), and increased levels of 8-isoprostanes (Alonso Fernandez 2009; Carpagnano et al., 
2003) have been observed. 
Among the most important vasoconstrictive substances is endothelin-1, a peptide hormone 
secreted under the influence of hypoxia (Kanagy et al., 2001). Several studies have reported 
higher endothelin-1 levels in OSAS patients (Phillips et al 1999; Saarelainen & Hasan, 2000) 
however, Grimpen reports conflicting findings (Grimpen et al., 2000). This divergence might 
be explained by differences in study design. The groups studied by Phillips  (Phillips et al., 
1999) and Saarelainen (Saarelainen & Hasan, 2000) had more severe disease and, thus, 
underwent more severe oxygen desaturations that acted as a trigger for endothelin-1 secretion. 
Gjorup showed that hypertensive OSAS patients had greater nocturnal and diurnal 
endothelin-1 plasma levels than healthy controls, suggesting that OSAS does not affect plasma 
endothelin-1 levels in the absence of coexistent cardiovascular diseases (Gjorup et al., 2007). 
The inconsistency of the above endothelin-1 levels likely reflects the predominantly 
abluminal release of endothelin. Using rat models of arterial hypertension, several authors 
have reported elevated vascular production of endothelin-1, while circulating levels 
remained similar to controls (Pohl & Busse, 1989; Rossi & Pitter, 2006). This demonstrates 
that circulating levels of endothelin-1 do not exclude elevated vascular production in OSAS.  
In recent years, endothelial progenitor cells have gained a central role in vascular 
regeneration and endothelial repair capacity through angiogenesis and restoring endothelial 
function of injured blood vessels. Endothelial progenitor cells are decreased in patients with 
endothelial dysfunction and underlie an increased risk for cardiovascular morbidity in 
OSAS. Endothelial progenitor cells may have a potential role in the pathogenesis of vascular 
diseases that is pertinent to OSAS (Berger & Lavie, 2011). 
It has recently been reported that OSAS patients presented increased oxidant production in 
the microcirculation and endothelial dysfunction, both of which improved with treatment 
(Patt et al., 2010) 
8. OSAS and endocrine-metabolic consequences 
Even though OSAS is generally less prevalent in women than men, differences diminish 
after the onset of menopause. This may be the result of declining estrogen and progesterone 
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(Resta et al., 2004; Anttalainen et al., 2006). Accordingly, estrogen replacement therapy in 
menopausal women lessens the prevalence of OSAS (Shahar et al., 2003; Wesstrom et al., 
2005).  
On the other hand, men diagnosed with OSAS may manifest decreased libido and a decline 
in morning serum testosterone levels (Teloken et al., 2006; Hoekema et al., 2006). At first, 
this was thought to reflect an associated dysfunction of the pituitary-gonadal axis related to 
sleep fragmentation and hypoxia (Meston et al., 2003). However, the correction of hypoxia 
and sleep fragmentation in OSAS patients treated with CPAP does not lead to complete 
recovery, suggesting that existence of other underlying causes. In a recent study, with the 
exception of prolactine, CPAP therapy produced no significant changes the serum level of 
sexual hormones including FSH and  LH (Macrea et al., 2010). Some authors claim that 
obesity is the major contributing factor to the reduced pituitary gonadal function in OSAS 
(Luboshitzky et al., 2005).  
9. Obesity 
Central, or visceral, obesity is associated with the greatest risk for OSAS (Shinohara et al., 
1997). The mechanism by which obesity can favor the onset of OSAS is not well-known, but 
it could be that central obesity precipitates or exacerbates OSAS because fat deposits in the 
upper airway affect distensibility (Isono, 2009). The increased volume of abdominal fat 
could predispose to hypoventilation during sleep and/or reduce the oxygen reserve, 
favoring oxygen desaturation during sleep (Schwartz et al., 2008). In addition, the disrupted 
sleep patterns characteristic of OSAS predispose to metabolic effects and weight gain. Patel 
investigated the association between self-reported usual sleep duration and subsequent 
weight gain in the Nurses' Health Study. They showed that a habitual sleep time of less than 
7 hours is associated with a modest increase in future weight gain and incident obesity 
(Patel et al., 2006). 
In recent years, much attention has been focused on the interaction between OSAS and 
products released by adipose tissue such as leptin, adiponectin, resistin and grelin (Ronti et 
al., 2006).  
Leptin is an adipocyte-derived hormone that regulates body weight through control of 
appetite and energy expenditure (Proulx et al., 2002). Furthermore, leptin is a cytokine and 
is therefore also involved in the inflammatory process. Several studies have shown 
increased levels of leptin in OSAS (Phillips et al., 2000; Tokuda et al., 2008), suggesting its 
role in the disease (Ip et al., 2000). The mechanisms underlying the relation between leptin 
and OSAS are very diverse, and may involve overnight changes in apnea levels (Patel et al., 
2004; Sanner et al., 2004), sleep hypoxemia (Tatsumi et al., 2005), and hypercapnia (Shimura 
et al., 2005).  
A direct relationship between OSAS and leptin is supported by the fact that effective OSAS 
treatment with CPAP also influences leptin levels (Shimizu et al., 2002; Cuhadaroglu et al., 
2009). Although the precise mechanism explaining the effect of CPAP has not yet been 
elucidated, it can be inferred that reduction in sympathetic activity (Snitker et al., 1997), and 
improvement in insulin sensitivity play a role (Brooks et al., 1994).  
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Leptin levels have been proposed as a prognostic marker for OSAS (Ozturk et al., 2003) and 
have been implicated in the pathogenesis of OSAS-related cardiovascular disease 
(Kapsimalis et al., 2008; Tokuda et al., 2008; Al et al., 2009).  
Leptin can also act as a respiratory stimulant, and impairment of the leptin signaling 
pathway causes respiratory depression in mice (O'Donnell et al., 2000). This hormone has 
been associated with obesity hypoventilation syndrome in humans (Phipps et al., 2002) and 
may reflect a compensatory response to hypoventilation (Makinodan et al., 2008).  
OSAS has independently been associated with reduced levels of adiponectin (Masserini et 
al., 2006; Zhang et al., 2006; Carneiro et al., 2009) which may favour cardiovascular disease 
development. The recurrent hypoxia-reoxygenation attacks in OSAS patients may activate 
oxidative stress and lead to low levels of adiponectin (Vatansever et al., 2010). 
Some authors have observed that serum adiponectin levels may be independent of the 
degree of OSAS (Tokuda et al., 2008). Decreased adiponectin may result from increased 
sympathetic activity (Delporte et al., 2002), and higher levels of cytokines such as IL-6 and 
TNF (Fasshauer et al., 2003).  In fact, there are conflicting reports as to whether CPAP 
treatment of OSAS effectively normalizes adiponectin levels (de Lima et al., 2010). 
Obesity has been implicated in the relation between OSAS and adiponectin  (Makino et al., 
2006), In a recent study involving media under hypoxic conditions in an ex-vivo mouse 
model, adiponectin secretion was measured. In obese mice, hypoxic stress reduced 
adiponectin in the supernatant of mesenteric fat tissue, but not subcutaneous fat tissue. 
These findings suggest that abdominal obesity, representing abundant mesenteric fat tissue 
susceptible to hypoxic stress, partly explains adiponectin levels in OSAS patients, and that 
reduction of visceral fat accumulation may combat OSAS-related atherosclerotic 
cardiovascular diseases in abdominal obesity (Nakagawa et al., 2011). 
Resistin is a white adipose tissue hormone whose function has yet to be established. In a 
study of 20 obese OSAS patients, Harsch found that CPAP treatment of OSAS had no 
significant influence on resistin levels (Harsch et al., 2004). In OSAS patients, hypoxic stress 
during sleep may enhance resistin production, possibly mediating systemic inflammatory 
processes. Through its effect on OSAS, CPAP therapy may help control resistin production 
(Yamamoto et al., 2008). 
OSAS may decrease serum resistin levels in subjects with excess body mass and also may 
contribute to glucose metabolism, but has no influence on leptin levels (Wysocka et al., 2009) 
Ghrelin is a hormone that influences appetite and fat accumulation and its physiological 
effects are opposite to those of leptin. No clear relation has been found between ghrelin and 
OSAS. In a study of 30 obese OSAS patients, Harsch found that plasma ghrelin levels were 
significantly higher in OSAS patients than in controls. These elevated ghrelin levels could 
not be explained by obesity alone, since they rapidly decreased with CPAP therapy (Harsch 
et al., 2003). In another study of 30 untreated obese patients with moderate-severe OSAS, 
significantly higher levels of serum leptin were found in OSAS patients than in controls, but 
ghrelin levels were no different (Ulukavak et al., 2005). 
In a recent study of 55 consecutive OSAS patients, the study group presented significantly 
higher serum ghrelin levels than controls. There was a significant positive correlation 
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between ghrelin and AHI. No significant difference was noted in the levels of leptin, 
adiponectin, and resistin (Li et al., 2010). 
Increased ghrelin levels have been found to support the presence of increased appetite and 
caloric intake in obese patients with OSAS, which in turn may further promote the severity 
of the underlying conditions (Spruyt et al., 2010). In obese children, OSAS is associated with 
daytime sleepiness, elevation of proinflammatory cytokines, increased leptin, and decreased 
adiponectin (Tsaoussoglou et al., 2010).  
10. OSAS and insulin resistance 
A variety of studies based on animal models indicate that hypoxia can alter glucose 
homeostasis (Cheng et al., 1997; Li et al., 2006). Polotsky described that long-term exposure 
to intermittent hypoxia increased levels of insulin and glucose intolerance in obese, leptin-
deficient mice (Polotsky et al., 2003). Humans exposed to hypoxia present worsened glucose 
tolerance (Braun et al., 2001).  
Insulin resistance is a central part of the metabolic syndrome, a condition that is reaching 
epidemic proportions in Western Society and now emerging in developing countries 
(Prentice, 2006). Most studies involving OSAS and insulin resistance demonstrate an 
association between these two diseases, independently of obesity (Tassone et al., 2003; 
McArdle et al., 2007). In a large population-based study involving normoglycemic 
hypertensive men, Resnick found that the severity of OSAS was associated with increased 
insulin resistance (Resnick et al., 2003). The magnitude of these beneficial effects is 
modulated by the hours of CPAP adherence and the degree of obesity (Tasali et al., 2011).  
Insulin resistance is associated to states of inflammation (Reaven, 2005). Monocyte 
chemoattractant protein-1 levels are elevated in OSAS and may be involved in the 
pathogenesis of insulin resistance in these patients  (Piemonti et al., 2003; Hayashi et al., 
2006). 
11. Metabolic syndrome and OSAS  
Metabolic syndrome is an emerging public health problem that represents a constellation of 
cardiovascular risk factors (Batsis et al., 2007). The clinical identification of metabolic 
syndrome is based on measures of abdominal obesity, atherogenic dyslipidemia, elevated 
blood pressure, and glucose intolerance (Executive Summary of the NCEP., 2001).  
Although the etiology of this syndrome is largely unknown, it is likely to be comprised of a 
complex interaction between genetic, metabolic, and environmental factors (Nestel, 2003). 
Several recent studies suggest that a proinflammatory state may also be an important 
component (Aso et al., 2005; Gude et al., 2009). The close association between OSAS and 
metabolic syndrome is called “Syndrome Z”(Wilcox et al., 1998) 
The prevalence of metabolic syndrome is markedly higher among OSAS patients. Ambrosetti 
et al. studied 89 consecutive OSAS patients and found metabolic syndrome in 53% of them 
(Ambrosetti et al., 2006). Another recent study found a prevalence of 68% (Drager et al., 2009). 
Obese OSAS patients may have an increased rate of metabolic syndrome and higher levels of 
serum lipids, fasting glucose, leptin and fibrinogen than obese subjects without OSAS. Thus, 
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clinicians should be encouraged to systematically evaluate the presence of metabolic 
abnormalities in OSAS and vice versa (Basoglu et al., 2011). 
Both clinical and animal studies suggest that an independent relationship may exist between 
OSAS and hyperlipidemia. Hypoxic stress produced by OSAS potentially increases the risk 
of hyperlipidemia. In rodent models, hyperlipidemia can result from exposure to 
intermittent hypoxia (Li et al., 2005). In a sample of nearly 5,000 subjects from the Sleep 
Heart Health study, there was a positive association between OSAS severity and increased 
serum total cholesterol and triglycerides, as well as decreased serum HDL, in people under 
the age of 65 (Newman et al., 2001). 
In a population-based sample of four hundred women aged 20-70 years the frequency of 
metabolic syndrome increased from 10.5% in women with AHI <5 to 57.1% in women with 
AHI ≥ 30. AHI and minimal saturation level remained significantly associated with 
metabolic syndrome also when adjusting for the waist-to-hip-ratio (Theorell-Haglow et al., 
2011). 
Both OSAS and metabolic syndrome may exert negative synergistic effects on the 
cardiovascular system through multiple mechanisms (Bonsignore & Zito, 2008; Levy et al., 
2009).  
Intermittent hypoxia, the hallmark feature of OSAS, leads to a preferential activation of 
inflammatory pathways. Oxidative stress, cardiovascular inflammation, endothelial 
dysfunction, and metabolic abnormalities in OSAS could accelerate atherogenesis (Quercioli 
et al., 2010).  Further studies are required to determine the precise role of inflammation in 
the cardiovascular pathogenesis of OSAS, particularly its interaction with oxidative stress, 
obesity and metabolic dysfunction (Kent et al., 2011) 
12. Conclusions 
OSAS patients experience hypoxia–reoxygenation episodes, hypercapnia and arousal from 
sleep with modifications in the autonomic nervous system, oxidative stress and 
inflammation. OSAS is frequently associated to endocrine metabolic alterations and obesity.  
 Inflammatory processes play an important role in the pathogenesis of atherosclerosis and 
circulating levels of several inflammation markers have been associated with future 
cardiovascular risk. OSAS plays a mediating role between obesity and cardiovascular 
disease. Clinical and experimental data suggest a relationship between OSAS and adipose 
tissue pathophysiology which appears biologically plausible, however, further research is 
still needed. Multiple factors have been proposed to activate proinflammatory pathways in 
obesity, including generation of reactive oxygen species, and release of inflammatory 
cytokines potentially activated by OSAS-related hypoxic stress. All of this indicates that, 
more than a local abnormality, OSAS should be considered a systemic disease.  
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